ArticleBiology direct2026
Hypoxia and lactate metabolism-related gene COL5A3 promotes triple negative breast cancer progression via DDR1/FAK/PI3K/AKT pathway.
Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTriple-negative breast cancer (TNBC) is a highly aggressive subtype characterized by a lack of hormone receptors and specific molecular targets, leading to limited treatment options, high recurrence rates, and poor clinical prognosis. The Warburg effect in cancer cells generates a tumor microenvironment characterized by hypoxia, low glucose, and high lactate levels, which severely promotes chemoresistance, immune escape, and distant metastasis. Nevertheless, the prognostic significance of hypoxia and lactate metabolism-related genes in TNBC remains largely unclear, and more accurate prediction models are urgently needed.
methodsClinical information and gene expression profiles of patients with TNBC were obtained from online databases. LASSO and multivariate Cox regression analyses were used to establish the hypoxia and lactate metabolism-related prediction model, and the prognostic value was further validated using Kaplan-Meier plotter, receiver operating characteristic curves, and nomogram. Gene set enrichment analysis was performed to evaluate the pathways and molecular functions. Tumor mutation, microsatellite instability, RNA expression-based stemness scores, immune infiltration, and drug susceptibility analyses were performed to identify potential therapeutic targets. Single-cell transcriptome data were processed and quality-controlled using Seurat. Monocle2, CellChat, and ssGSEA analyses were used to investigate the relationship between COL5A3, malignant phenotype, and tumor microenvironment. A series of in vitro experiments was performed to evaluate the biological functions of hub gene COL5A3.
resultsFive genes, COL5A3, LRRC8D, IGFL1, SEPTIN3, and PEG10, were identified to establish the hypoxia and lactate metabolism-related risk score. TNBC patients divided into high-risk or low-risk groups according to the risk score exhibited substantial differences in survival outcome, tumor mutation, immune infiltration, and drug sensitivity. The constructed model showed strong predictive performance, with receiver operating characteristic curves showing area under the curve values of 0.82, 0.86, and 0.90 at 365, 1085, and 1825 days, respectively. Single-cell analysis showed that high COL5A3 expression was associated with greater proliferative capacity, drug resistance, and stemness. COL5A3 is also involved in regulating the interaction between TNBC cells and other cells in the tumor microenvironment. In vitro studies have indicated that COL5A3 could promote tumor proliferation, migration, invasion, and drug resistance via the DDR1/FAK/PI3K/AKT pathway in TNBC cells. OF-1 was initially identified as a candidate compound with potential therapeutic relevance for TNBC.
conclusionA novel hypoxia and lactate metabolism-related gene signature could be used for prognosis prediction in TNBC patients, and the hub gene COL5A3 promotes TNBC progression via the DDR1/FAK/PI3K/AKT pathway. Further research is needed to explore the biological roles of these genes in TNBC to refine the therapeutic approaches.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.